Macquarie Group’s Coherus Oncology CHRS Stock Holding History

Macquarie Group’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-899,999	Closed	-$1.48M	–	983
2025 Q3	$1.48M	Hold	899,999	–	–	﹤0.01%	1252
2025 Q2	$658K	Hold	899,999	–	–	﹤0.01%	1433
2025 Q1	$726K	Hold	899,999	–	–	﹤0.01%	1428
2024 Q4	$1.24M	Hold	899,999	–	–	﹤0.01%	1311
2024 Q3	$936K	Hold	899,999	–	–	﹤0.01%	1392
2024 Q2	$1.56M	Hold	899,999	–	–	﹤0.01%	1288
2024 Q1	$2.15M	Buy	899,999 +250,000	+38%	+$615K	﹤0.01%	1199
2023 Q4	$2.17M	Buy	649,999 +151,400	+30%	+$406K	﹤0.01%	1200
2023 Q3	$1.86M	Buy	498,599 +68,599	+16%	+$317K	﹤0.01%	1177
2023 Q2	$1.84M	Hold	430,000	–	–	﹤0.01%	1206
2023 Q1	$2.94M	Hold	430,000	–	–	﹤0.01%	1045
2022 Q4	$3.41M	Sell	430,000 -591	-0.1%	-$4.55K	﹤0.01%	1054
2022 Q3	$4.14M	Sell	430,591 -784	-0.2%	-$7.93K	0.01%	1038
2022 Q2	$3.12M	Hold	431,375	–	–	﹤0.01%	1150
2022 Q1	$5.57M	Hold	431,375	–	–	﹤0.01%	1088
2021 Q4	$6.88M	Hold	431,375	–	–	0.01%	1043
2021 Q3	$6.93M	Hold	431,375	–	–	0.01%	1016
2021 Q2	$5.97M	Hold	431,375	–	–	﹤0.01%	1081
2021 Q1	$6.3M	Sell	431,375 -371	-0.1%	-$6.3K	0.01%	852
2020 Q4	$7.5M	Hold	431,746	–	–	0.01%	787
2020 Q3	$7.92M	Hold	431,746	–	–	0.01%	705
2020 Q2	$7.71M	Buy	431,746 +1,746	+0.4%	+$29.6K	0.01%	682
2020 Q1	$6.97M	Hold	430,000	–	–	0.01%	639
2019 Q4	$7.74M	Hold	430,000	–	–	0.01%	698
2019 Q3	$8.71M	Hold	430,000	–	–	0.01%	632
2019 Q2	$9.5M	Hold	430,000	–	–	0.02%	615
2019 Q1	$5.87M	Sell	430,000 -300	-0.1%	-$4K	0.01%	734
2018 Q4	$3.9M	Hold	430,300	–	–	0.01%	815
2018 Q3	$7.1M	Sell	430,300 -2,700	-0.6%	-$47.9K	0.01%	710
2018 Q2	$6.06M	Buy	433,000 +13,000	+3%	+$186K	0.01%	736
2018 Q1	$4.64M	Buy	420,000 +23,700	+6%	+$259K	0.01%	776
2017 Q4	$3.49M	Buy	396,300 +106,300	+37%	+$1.14M	0.01%	871
2017 Q3	$3.87M	Sell	290,000 -20,923	-7%	-$277K	0.01%	819
2017 Q2	$4.46M	Buy	310,923 +263,168	+551%	+$5.06M	0.01%	775
2017 Q1	$1.01M	Buy	47,755 +5,200	+12%	+$128K	﹤0.01%	1177
2016 Q4	$1.2M	Sell	42,555 -15,700	-27%	-$439K	﹤0.01%	1115
2016 Q3	$1.56M	Buy	58,255 +2,700	+5%	+$73.7K	﹤0.01%	1031
2016 Q2	$938K	Buy	+55,555	New	+$1.04M	﹤0.01%	1157

Other funds holding CHRS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TGY2IT

Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

Macquarie Group's CHRS Position: Q4 2025 in Review

Macquarie Group sold out of Coherus Oncology (CHRS) in Q4 2025, closing a stake of 899,999 shares — an estimated $1.48M sold.

Macquarie Group first reported a position in CHRS in Q2 2016 and held it in 38 quarters. The position peaked at $9.5M in Q2 2019. 128 funds tracked by Wall St. Rank hold CHRS as of Q4 2025.

Macquarie Group reported no remaining Coherus Oncology position as of Q4 2025 after selling out during the quarter.
Macquarie Group sold 899,999 Coherus Oncology shares in Q4 2025, an estimated $1.48M.
Macquarie Group first reported a position in Coherus Oncology in Q2 2016 and held it in 38 quarters.
Macquarie Group's Coherus Oncology position peaked at $9.5M in Q2 2019.
128 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2025.

Based on Macquarie Group's 13F filing for Q4 2025, filed 13 Feb 2026.